Literature DB >> 8460052

Effects of excitatory amino acid receptor antagonists on a capsaicin-evoked nociceptive reflex: a comparison with morphine, clonidine and baclofen.

Brian Ault1, Lee M Hildebrand.   

Abstract

The rat isolated spinal cord-tail preparation has been employed to examine the effects of several antinociceptive drugs and excitatory amino acid (EAA) receptor antagonists on nociceptive reflexes (recorded in ventral roots) stimulated by peripheral application of capsaicin (CAP). Non-nociceptive monosynaptic and polysynaptic dorsal root-evoked ventral root potentials (DR-VRPs) were also examined. Morphine (0.01-3 microM) and clonidine (0.03-1 microM) inhibited CAP-stimulated activity, but not the non-nociceptive dorsal root-evoked monosynaptic reflex (MSR) or polysynaptic (PSR) activity. These effects were antagonized by naloxone and efaroxan, respectively. The AMPA/KA receptor antagonists CNQX (0.1-100 microM) and DNQX (0.1-30 microM) blocked nociceptive activity and were 4-fold selective for CAP-evoked potentials compared to the monosynaptic reflex. Kynurenate (1-300 microM), DL-AP-4 (3-300 microM), L-AP-4 (3-300 microM), and the GABAB receptor agonist baclofen (0.1-10 microM), inhibited all evoked potentials with relatively little selectivity between nociceptive and non-nociceptive responses. NMDA receptor antagonism by AP-5 (100 microM) reduced nociceptive and non-nociceptive potentials by a maximum of 30-33%. These data indicate that AMPA/KA receptor-mediated synapses are involved in acute spinal nociceptive transmission and suggest that AMPA/KA receptor subtypes could provide novel analgesic targets.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8460052     DOI: 10.1016/0304-3959(93)90168-O

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  9 in total

Review 1.  Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms.

Authors:  Kenneth E Miller; E Matthew Hoffman; Mathura Sutharshan; Ruben Schechter
Journal:  Pharmacol Ther       Date:  2011-01-26       Impact factor: 12.310

2.  Suppression of stretch reflex activity after spinal or systemic treatment with AMPA receptor antagonist NGX424 in rats with developed baclofen tolerance.

Authors:  Masakatsu Oshiro; Michael P Hefferan; Osamu Kakinohana; Nadezda Lukacova; Kazuhiro Sugahara; Tony L Yaksh; Martin Marsala
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  Central Control of Peripheral Joint Inflammation and Heat Hyperalgesia.

Authors:  Kathleen A Sluka; William D Willis; Karin N Westlund
Journal:  Prog Pain Res Manag       Date:  1994-01-01

Review 4.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

5.  Group III metabotropic glutamate receptors and transient receptor potential vanilloid 1 co-localize and interact on nociceptors.

Authors:  R M Govea; S Zhou; S M Carlton
Journal:  Neuroscience       Date:  2012-05-17       Impact factor: 3.590

6.  Ethanol withdrawal hyper-responsiveness mediated by NMDA receptors in spinal cord motor neurons.

Authors:  Hui-Fang Li; Joan J Kendig
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

7.  [Antinociceptive effects of alpha(2)-adrenoceptor agonists ("analgesic" actions in animal experiments)agonists ("analgesic" actions in animal experiments).].

Authors:  I Jurna
Journal:  Schmerz       Date:  1995-11       Impact factor: 1.107

Review 8.  The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects.

Authors:  K McCormack
Journal:  Drugs       Date:  1994       Impact factor: 9.546

9.  How Gastrin-Releasing Peptide Opens the Spinal Gate for Itch.

Authors:  Martina Pagani; Gioele W Albisetti; Nandhini Sivakumar; Hendrik Wildner; Mirko Santello; Helge C Johannssen; Hanns Ulrich Zeilhofer
Journal:  Neuron       Date:  2019-05-15       Impact factor: 17.173

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.